ES2904533T3 - Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos - Google Patents

Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos Download PDF

Info

Publication number
ES2904533T3
ES2904533T3 ES14868142T ES14868142T ES2904533T3 ES 2904533 T3 ES2904533 T3 ES 2904533T3 ES 14868142 T ES14868142 T ES 14868142T ES 14868142 T ES14868142 T ES 14868142T ES 2904533 T3 ES2904533 T3 ES 2904533T3
Authority
ES
Spain
Prior art keywords
cells
mice
ganglioside
carbohydrate
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14868142T
Other languages
English (en)
Spanish (es)
Inventor
H Uri Saragovi
Wenyong Tong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AOA Dx Inc
Original Assignee
AOA Dx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AOA Dx Inc filed Critical AOA Dx Inc
Application granted granted Critical
Publication of ES2904533T3 publication Critical patent/ES2904533T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES14868142T 2013-12-06 2014-12-04 Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos Active ES2904533T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912684P 2013-12-06 2013-12-06
PCT/CA2014/051165 WO2015081438A1 (en) 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies

Publications (1)

Publication Number Publication Date
ES2904533T3 true ES2904533T3 (es) 2022-04-05

Family

ID=53272688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14868142T Active ES2904533T3 (es) 2013-12-06 2014-12-04 Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos

Country Status (7)

Country Link
US (1) US10363305B2 (enExample)
EP (2) EP3077405B1 (enExample)
JP (1) JP2016539172A (enExample)
CN (1) CN106414472A (enExample)
CA (1) CA2968995A1 (enExample)
ES (1) ES2904533T3 (enExample)
WO (1) WO2015081438A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof
KR20230155419A (ko) * 2020-10-05 2023-11-10 에이오에이 디엑스 암 진단을 위한 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221420B1 (en) * 1993-01-22 2002-09-28 Sloan Kettering Inst Cancer Ganglioside-protein conjugate vaccines
US7422733B2 (en) * 2000-11-29 2008-09-09 Bracco International B.V. Linkable sialyl Lewis X analogs
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
JP2003073397A (ja) 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
JP4742339B2 (ja) 2005-06-14 2011-08-10 独立行政法人産業技術総合研究所 シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
US20090181362A1 (en) * 2005-09-02 2009-07-16 Yasuo Suzuki Method for determination of recognition specificity of virus for receptor sugar chain
JP2008031156A (ja) 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Also Published As

Publication number Publication date
EP3077405B1 (en) 2021-11-03
EP3077405A4 (en) 2017-08-09
CN106414472A (zh) 2017-02-15
WO2015081438A1 (en) 2015-06-11
US20160303227A1 (en) 2016-10-20
EP3077405A1 (en) 2016-10-12
CA2968995A1 (en) 2015-06-11
US10363305B2 (en) 2019-07-30
JP2016539172A (ja) 2016-12-15
EP3957327A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
AU2015305332B2 (en) Novel glycan conjugates and use thereof
US9493580B2 (en) Multivalent glycopeptide constructs and uses thereof
KR101806370B1 (ko) 보다 높은 탄수화물 항원 밀도 및 신규한 사포닌 애쥬번트를 갖는 백신
US20150064240A1 (en) MUC1 Based Glycolipopeptide Vaccine with Adjuvant
Song et al. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model
Fernandez-Tejada et al. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol
AU2009268349A1 (en) Glycopeptide constructs and uses thereof
WO2008031126A1 (en) Multi-component tumour vaccine
Mat Rani et al. Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers
US20240042000A1 (en) Carbohydrate structures and uses thereof
ES2904533T3 (es) Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos
AU2018359358B2 (en) Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
US20180264093A1 (en) Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
HK40064500A (en) Anti-ganglioside compound for targeting cancer and generating antibodies
WO2022083805A1 (es) Antígeno quimérico que comprende el dominio extracelular de pd-l1
Tong et al. A synthetic GD2 carbohydrate tetramer vaccine elicits tumor-killing antibodies and is therapeutic against GD2+ tumors
HK1213266B (zh) 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
BR122023010749B1 (pt) Saponina obi-821
BR112015016381B1 (pt) Vacina, e, composição farmacêutica